INTRODUCTION {#s1}
============

Breast cancer (BC), the most frequent malignant neoplasm among female worldwide, accounts for approximate 25% of women malignant tumor. It is reported that 1.67 million people were diagnosed as BC ever year, therefore it has become a serious health issue, especially in the developing countries \[[@R1]\]. It is well known that the lifetime presence of the estrogen in the blood is an important pathogenic factor of BC, and this is in consistence with the low incidence of the breast cancer in males that is due to the lower estrogen levels and lower breast tissue volume. By now, researches on the status of hormone receptors and/or menopause associated with genetic alterations in BC risk have attracted an increasing number of attention, and lots of genes, including BRIPI, CHEK2, MDM, TGFB, TP53, BRCA1, BRCA2, and PTEN, and also several gene polymorphisms. Among genes of this family, CYP17, CYP19 and CYP1A1 have important functions in synthesis, metabolism and maintaining the levels of the androgen and estrogen hormones \[[@R2]\]. Previous published reasearches have demonstrated that estrogen act as a crucial role in the formation of BC; in addition, evidences have also been found about the positive role of cell surface receptors of estrogen in tumorigenesis \[[@R3]\]. Nevertheless, the precise mechanism behind estrogen in the formation of BC remains unknown. Previous studies have indicated that cytochrome P450c17α, which is a key enzyme in the synthesis of estrogen, and could increase the breast neoplasm risk \[[@R4]\]. The cytochrome P450c17α enzyme, predominantly catalyzes the formation of the precursor dehydroepiandrosterone (DHEA). Meanwhile, precursor DHEA could further be converted into estrogen through a succession of tissue-specific pathways \[[@R5], [@R6]\]. Estrogen, plays a vital part in the etiology of BC and identified the risk between estrogen and BC could well elucidate the biosynthesis and metabolism mechanisms. So far, more and more researches have demonstrated the correlation of estrogen-related genes genetic variations with BC risk. The CYP17T-34C (rs743572) polymorphism which is located on the human chromosome 10, in the 50-untranslated region has been most commonly reported \[[@R7]\].

Many studies about the genetic mutations or SNP occurring in CYP17 gene could enhance CYP17's transcription rate and increase the enzyme cytochrome P450c17 level, resuling in an increasing number of bioavailable estrogen, which is likely to affect the risk and aggressiveness of BC \[[@R8]\]. But many previous article results between rs743572 mutations and BC risk remain conflicting: Han's research \[[@R9]\] revealed that no statistically meaningful correlation of rs743572 with risk of BC. However, significant correlation was found between rs743572 and BC risk in another research on the same theme \[[@R10]\]. Since few new high-quality investigations were published, we performed this study to take a more precise evaluation of rs743572 with the risk of BC.

RESULTS {#s2}
=======

The main feature of included studies {#s2_1}
------------------------------------

As showed in Figure [1](#F1){ref-type="fig"}, 331 references were retrieved at first based on our selection strategy. 186 papers were remained after removing the duplicate reports. After reading titles and abstracts, we excluded 104 studies which were clearly unrelated. In the end, the whole of the rest of the papers were checked based on the inclusion and exclusion criteria. Finally, forty-nine studies on rs743572 and the risk of BC were eventually included in our study. Thirteen articles showed the number of three genotypes (TT, TC, and CC) among premenopausal women, and thirteen studies report TT, TC, and CC number in postmenopausal women. Main information of included studies were shown in Table [1](#T1){ref-type="table"}. Among these qualified researches, seventeen were performed in Asians, twenty-five in Caucasians, one in Africans, one in both Asians and Caucasians, one in both Africans and Caucasians, and four in mixed ethnicity. Moreover, twenty-two studies were considered as moderate-quality studies (NOS scores of these researches were 4--6), and other twenty-seven studies were considered as high-quality studies (NOS scores of these studies were seven or above). Except for four included researches were not in agreement with Hardy--Weinberg equilibrium (HWE), genotype distributions in the control groups of other 45 researches were all satisfied with HWE.

![Flow diagram of the selection of the studies in this meta-analysis](oncotarget-09-4200-g001){#F1}

###### Characteristics of studies included in the meta-analysis

  First author                Year   Country       Ethnicity   Source of control   Number (case/control)   HWE (*P* value)   NOS
  --------------------------- ------ ------------- ----------- ------------------- ----------------------- ----------------- -----
  Dunning \[[@R17]\]          1998   UK            Caucasian   PB                  835/591                 0.261             7
  Weston \[[@R21]\]           1998   USA           Caucasian   HB                  103/205                 0.449             6
  Weston \[[@R21]\]           1998   USA           African     HB                  20/35                   0.253             6
  Helzlsouer \[[@R22]\]       1998   USA           Caucasian   PB                  109/113                 0.549             6
  Bergman \[[@R23]\]          1999   Sweden        Caucasian   PB                  109/117                 0.304             6
  Haiman \[[@R24]\]           1999   USA           Caucasian   PB                  436/618                 0.391             7
  Huang \[[@R25]\]            1999   China         Asian       PB                  123/126                 0.972             6
  Young \[[@R26]\]            1999   UK            Caucasian   PB                  39/58                   0.732             5
  Kristensen \[[@R27]\]       1999   Norway        Caucasian   PB                  510/201                 0.351             7
  Hamajima \[[@R28]\]         2000   Japan         Asian       HB                  144/166                 0.044             6
  Kuligina \[[@R29]\]         2000   Russia        Caucasian   HB                  240/182                 0.017             6
  Mitrunen \[[@R30]\]         2000   Finland       Caucasian   PB                  479/480                 0.967             7
  Feigelson \[[@R18]\]        2001   USA           Mixed       PB                  850/1508                0.335             7
  Gudmundsdottir \[[@R31]\]   2003   Iceland       Caucasian   PB                  500/395                 0.131             7
  Wu \[[@R32]\]               2003   Singapore     Asian       PB                  188/671                 0.512             6
  Ambrosone \[[@R33]\]        2003   USA           Caucasian   PB                  207/188                 0.130             7
  Tan \[[@R34]\]              2003   China         Asian       PB                  250/250                 0.117             7
  Hefler \[[@R35]\]           2004   Austria       Asian       PB                  388/1698                0.455             7
  Ahsan \[[@R36]\]            2004   USA           Mixed       HB                  313/271                 0.457             6
  Chacko \[[@R37]\]           2005   India         Asian       HB                  140/140                 0.133             6
  Einarsdo´ttir \[[@R38]\]    2005   Sweden        Caucasian   PB                  1499/1338               0.885             7
  Shin \[[@R39]\]             2005   Korean        Asian       HB                  462/337                 0.134             7
  Verla-Tebit \[[@R40]\]      2005   Germany       Caucasian   PB                  527/904                 0.380             7
  Hopper \[[@R41]\]           2005   Australia     Caucasian   PB                  1404/788                0.697             7
  Onland-More \[[@R42]\]      2005   Netherlands   Caucasian   PB                  335/373                 0.189             7
  Han \[[@R9]\]               2005   China         Asian       PB                  210/427                 0.037             6
  Piller \[[@R43]\]           2006   Germany       Caucasian   PB                  608/1298                0.062             7
  Chakraborty \[[@R44]\]      2007   India         Asian       PB                  186/212                 0.550             6
  Setiawan \[[@R45]\]         2007   USA           Mixed       PB                  5147/6882               0.312             7
  Chen \[[@R46]\]             2008   USA           Caucasian   PB                  1037/1096               0.884             7
  Sakoda \[[@R47]\]           2008   China         Asian       PB                  615/877                 0.232             7
  Zhang \[[@R48]\]            2008   China         Asian       PB                  299/342                 0.454             7
  Samson \[[@R49]\]           2009   India         Asian       PB                  250/500                 0.720             7
  Sangrajrang \[[@R50]\]      2009   Thailand      Asian       HB                  564/489                 0.418             7
  Sobczuk \[[@R51]\]          2009   Poland        Caucasian   PB                  100/106                 0.503             6
  Antognelli \[[@R52]\]       2009   Italy         Caucasian   PB                  547/544                 0.982             7
  Hosseini \[[@R53]\]         2009   Iran          Caucasian   HB                  53/53                   0.057             5
  Jakubowska \[[@R54]\]       2009   Poland        Caucasian   HB                  319/290                 0.519             6
  MARIE-GENICA \[[@R55]\]     2009   Germany       Caucasian   PB                  3145/5487               0.254             7
  Kato \[[@R56]\]             2009   USA           African     PB                  184/189                 0.152             6
  Tuzuner \[[@R57]\]          2010   Turkey        Caucasian   PB                  55/91                   0.466             5
  Syamala \[[@R58]\]          2010   India         Asian       HB                  359/367                 0.464             7
  Surekha \[[@R59]\]          2010   India         Asian       PB                  249/249                 0.949             7
  Iwasaki \[[@R60]\]          2010   Japan         Asian       HB                  388/388                 0.299             6
  Iwasaki \[[@R60]\]          2010   Brazil        Asian       HB                  78/79                   0.144             6
  Iwasaki \[[@R60]\]          2010   Brazil        Caucasian   HB                  379/379                 0.039             6
  Kaufman \[[@R61]\]          2011   Mixed         Mixed       HB                  1175/829                0.944             7
  Cribb \[[@R10]\]            2011   Canada        Caucasian   HB                  207/621                 0.033             6
  Ghisari \[[@R62]\]          2014   Inuit         Asian       PB                  30/113                  0.882             5
  Chattopadhyay \[[@R63]\]    2014   India         Asian       PB                  360/360                 0.692             7
  Karakus \[[@R64]\]          2015   Turkey        Caucasian   PB                  199/197                 0.934             6
  Farzaneh \[[@R65]\]         2016   Iranian       Caucasian   PB                  124/100                 0.189             6

HWE: Hardy-Weinberg equilibrium for controls. PB: population-based study. HB: hospital-based study.

Meta-analysis results {#s2_2}
---------------------

Meta-analysis results among overall populations, distribution of this polymorphism in case groups and control groups are presented in Table [2](#T2){ref-type="table"}. For premenopausal women and postmenopausal women, distribution of this polymorphism in case groups and control groups are presented in Table [3](#T3){ref-type="table"}, and the main outcome of our study are shown in Tables [4](#T4){ref-type="table"} and [5](#T5){ref-type="table"}.

###### Genotype distribution of the CYP17 (rs743572) polymorphism in cases and controls among overall populations

  First author     Genotype (N)                                            
  ---------------- -------------- ----- ------ ------ ------ ------ ------ ------
  Dunning          835            130   402    303    591    85     277    229
  Weston           103            18    47     38     205    35     93     77
  Weston           20             3     10     7      35     2      18     15
  Helzlsouer       109            21    47     41     113    18     58     37
  Bergman          109            15    62     32     117    9      55     53
  Haiman           463            73    212    178    618    94     307    217
  Huang            123            44    54     25     126    35     63     28
  Young            39             5     13     21     58     7      28     23
  Kristensen       510            67    241    202    201    26     101    74
  Hamajima         144            20    83     41     166    27     95     44
  Kuligina         240            47    111    82     182    44     77     61
  Mitrunen         479            53    227    199    480    60     220    200
  Feigelson        850            149   409    292    1508   227    739    542
  Gudmundsdottir   500            60    247    193    395    66     173    156
  Wu               188            69    82     37     671    229    333    109
  Ambrosone        207            15    83     109    188    22     71     95
  Tan              250            89    115    46     250    89     110    51
  Hefler           388            75    186    127    1698   287    804    607
  Ahsan            313            49    155    109    271    51     140    80
  Chacko           140            6     40     94     140    3      22     115
  Einarsdo´ttir    1499           238   711    550    1338   212    638    488
  Shin             462            127   223    112    337    115    152    70
  Verla-Tebit      527            103   244    180    904    157    424    323
  Hopper           1404           230   621    553    788    113    364    311
  Onland-More      335            44    140    151    373    50     157    166
  Han              210            52    105    53     427    92     235    100
  Piller           608            119   289    200    1298   236    596    466
  Chakraborty      186            59    98     29     212    45     110    57
  Setiawan         5147           833   2445   1869   6882   1070   3338   2474
  Chen             1037           168   506    363    1096   175    523    398
  Sakoda           615            216   297    102    877    298    441    138
  Zhang            299            84    168    47     242    73     125    44
  Samson           250            32    91     127    500    54     226    220
  Sangrajrang      564            96    281    187    489    92     230    167
  Sobczuk          100            46    44     10     106    34     55     17
  Antognelli       547            60    258    229    544    68     249    227
  Hosseini         53             6     29     18     53     13     33     7
  Jakubowska       319            45    166    108    290    54     136    100
  MARIE-GENICA     3145           529   1573   1043   5487   941    2712   1834
  Kato             184            32    82     70     189    29     78     82
  Tuzuner          55             10    27     18     91     9      44     38
  Syamala          359            44    152    163    367    41     154    172
  Surekha          249            9     69     171    249    16     95     138
  Iwasaki          388            88    189    111    388    84     182    122
  Iwasaki          78             13    48     17     79     23     33     23
  Iwasaki          379            59    185    135    379    49     200    130
  Kaufman          1175           171   581    423    829    124    392    313
  Cribb            207            23    85     99     621    89     259    273
  Ghisari          30             6     12     12     113    32     57     24
  Chattopadhyay    360            14    116    230    360    7      93     260
  Karakus          199            18    79     102    197    15     78     104
  Farzaneh         124            22    70     32     100    17     56     27

###### Genotype distribution of the CYP17 (rs743572) polymorphism in cases and controls among premenopausal women and postmenopausal women

  First author    Genotype (*N*)                                        
  --------------- ---------------- ----- ----- ----- ------ ----- ----- -----
  Helzlsouer      24               4     9     11    25     4     13    8
  Bergman         109              15    62    32    117    9     55    53
  Mitrunen        163              15    71    77    203    27    88    88
  Wu              57               24    20    13    203    66    100   37
  Ambrosone       96               7     31    58    86     10    28    48
  Verla-Tebit     527              103   244   180   904    157   424   323
  Chen            334              55    153   126   373    69    174   130
  Samson          115              16    40    59    303    31    145   127
  Antognelli      187              18    81    88    230    31    99    100
  Kato            75               12    27    36    74     13    30    31
  Zhang           150              38    87    25    124    37    67    20
  Tan             95               32    45    18    97     30    40    27
  Han             117              25    61    31    163    36    85    42
  Helzlsouer      85               17    38    30    88     14    45    29
  Mitrunen        316              38    156   122   277    33    132   112
  Wu              131              45    62    24    468    163   233   72
  Ambrosone       111              8     52    51    102    12    43    47
  Einarsdo´ttir   1499             238   711   550   1338   212   638   488
  Onland-More     335              44    140   151   373    50    157   166
  Chen            680              111   339   230   677    96    333   248
  Samson          134              16    50    68    197    23    99    75
  Antognelli      360              42    177   141   314    37    150   127
  Kato            109              20    55    34    115    16    48    51
  Zhang           146              44    80    22    118    36    58    24
  Tan             155              57    70    28    153    59    70    24
  Han             93               27    44    22    264    56    150   58

###### Meta-analysis results among overall populations

  Comparisons                       OR     95% CI       *P* (OR)   Heterogeneity   Effects model   *P* (Begg)   *P* (Egger)   
  --------------------------------- ------ ------------ ---------- --------------- --------------- ------------ ------------- -------
  **Total**                                                                                                                   
  T VS C                            0.99   0.96--1.01   0.281      37.1%           0.005           R            0.856         0.766
  TT VS CC                          0.99   0.98--1.01   0.309      18.6%           0.127           F            0.987         0.408
  TC VS CC                          0.98   0.93--1.03   0.365      0.80%           0.457           F            0.825         0.563
  TT+TC VS CC                       0.98   0.93--1.02   0.287      15.0%           0.182           F            0.975         0.574
  TT VS TC+CC                       0.99   0.95--1.02   0.463      30.5%           0.022           R            1.000         0.902
  **Stratification by ethnicity**                                                                                             
  **Caucasian**                                                                                                               
  T VS C                            0.99   0.96--1.03   0.673      11.5%           0.294           F            \-            \-
  TT VS CC                          0.99   0.93--1.06   0.804      10.4%           0.233           F            \-            \-
  TC VS CC                          1.00   0.94--1.07   0.936      0.00%           0.467           F            \-            \-
  TT+TC VS CC                       1.00   0.94--1.06   0.604      11.1%           0.301           F            \-            \-
  TT VS TC+CC                       0.99   0.94--1.04   0.907      0.00%           0.596           F            \-            \-
  **Asian**                                                                                                                   
  T VS C                            0.97   0.89--1.06   0.574      60.8%           0.023           R            \-            \-
  TT VS CC                          0.99   0.95--1.02   0.483      33.9%           0.075           R            \-            \-
  TC VS CC                          0.97   0.88--1.07   0.525      11.4%           0.282           F            \-            \-
  TT+TC VS CC                       0.97   0.88--1.06   0.479      29.1%           0.114           F            \-            \-
  TT VS TC+CC                       0.97   0.84--1.11   0.652      60.0%           0.000           R            \-            \-
  **African**                                                                                                                 
  T VS C                            0.83   0.63--1.10   0.198      0.0%            0.621           F            \-            \-
  TT VS CC                          0.72   0.41--1.27   0.255      0.0%            0.393           F            \-            \-
  TC VS CC                          0.88   0.50--1.54   0.654      0.0%            0.363           F            \-            \-
  TT+TC VS CC                       0.80   0.47--1.36   0.408      0.0%            0.358           F            \-            \-
  TT VS TC+CC                       0.79   0.54--1.17   0.237      0.0%            0.859           F            \-            \-
  **Stratification by Source**                                                                                                
  **PB**                                                                                                                      
  T VS C                            0.98   0.95--1.00   0.102      35.2%           0.021           R            \-            \-
  TT VS CC                          0.95   0.90--1.01   0.073      18.7%           0.165           F            \-            \-
  TC VS CC                          0.95   0.90--1.00   0.047      0.0%            0.726           F            \-            \-
  TT+TC VS CC                       0.95   0.91--1.00   0.034      1.8%            0.439           F            \-            \-
  TT VS TC+CC                       0.99   0.95--1.02   0.474      32.4%           0.033           F            \-            \-
  **HB**                                                                                                                      
  T VS C                            1.03   0.97--1.09   0.299      38.9%           0.057           R            \-            \-
  TT VS CC                          1.10   0.97--1.24   0.128      18.2%           0.245           F            \-            \-
  TC VS CC                          1.14   1.02--1.28   0.024      0.0%            0.548           F            \-            \-
  TT+TC VS CC                       1.13   1.01--1.26   0.031      8.6%            0.355           F            \-            \-
  TT VS TC+CC                       0.99   0.91--1.08   0.847      30.6%           0.118           F            \-            \-
  **Stratification by HWE**                                                                                                   
  **Yes**                                                                                                                     
  T VS C                            0.99   0.96--1.01   0.250      41.2%           0.002           R            \-            \-
  TT VS CC                          0.97   0.93--1.02   0.288      26.6%           0.050           R            \-            \-
  TC VS CC                          0.99   0.98--1.01   0.421      0.0%            0.501           F            \-            \-
  TT+TC VS CC                       0.99   0.99--1.02   0.264      15.6%           0.180           F            \-            \-
  TT VS TC+CC                       0.98   0.95--1.02   0.381      35.3%           0.010           R            \-            \-

F: fixed effects model; R: random effects model.

###### Meta-analysis results among premenopausal women and postmenopausal women

  Comparisons          OR     95% CI       *P* (OR)   Heterogeneity   Effects model   *P* (Begg)   *P* (Egger)   
  -------------------- ------ ------------ ---------- --------------- --------------- ------------ ------------- ----
  **Premenopausal**                                                                                              
  T VS C               1.02   0.93--1.10   0.717      17.6%           0.267           F            \-            \-
  TT VS CC             1.01   0.85--1.20   0.885      6.4%            0.383           F            \-            \-
  TC VS CC             0.97   0.83--1.14   0.709      0.0%            0.492           F            \-            \-
  TT+TC VS CC          1.04   0.92--1.18   0.513      21.4%           0.227           F            \-            \-
  TT VS TC+CC          0.95   0.81--1.10   0.467      29.3%           0.151           F            \-            \-
  **Postmenopausal**                                                                                             
  T VS C               1.10   1.03--1.17   0.003      10.6%           0.339           F            \-            \-
  TT VS CC             0.96   0.84--1.10   0.539      0.0%            0.835           F            \-            \-
  TC VS CC             0.96   0.85--1.08   0.478      0.0%            0.902           F            \-            \-
  TT+TC VS CC          0.96   0.85--1.08   0.467      0.0%            0.930           F            \-            \-
  TT VS TC+CC          0.99   0.90--1.08   0.796      8.9%            0.357           F            \-            \-

F: fixed effects model; R: random effects model.

In overall populations, the association of CYP17 T-34C polymorphism with BC susceptibility was studied in forty-nine researches including 27,104 cases and 34,218 controls. No significant correlation was found between this polymorphism and BC susceptibility among any of the five genetic models: T/C (OR = 0.99, 95% CI = 0.96--1.01, *P* = 0.281), TT/CC (OR = 0.99, 95% CI = 0.98--1.01, *P* = 0.309), TC/CC (OR = 0.98, 95% CI = 0.93--1.03, *P* = 0.365), TT+TC/CC (OR = 0.98, 95% CI = 0.93--1.02, *P* = 0.287) and TT/TC+CC (OR = 0.99, 95% CI = 0.95--1.02, *P* = 0.463). Analogously, further subgroup analysis by ethnicity and source found similar results that in all the ethnic groups, HB group and PB group there is no significant correlation between rs743572 and BC susceptibility. Moreover, if we only analyze the studies with controls in agreement with HWE, no correlation between rs743572 and BC risk were observed (Table [4](#T4){ref-type="table"}) (Figure [2](#F2){ref-type="fig"}).

![Forest plots of associations between rs743572 and breast cancer risk\
(**A**) the overall populations in the allele contrast genetic model; (**B**) limiting the analysis to studies with controls in agreement with HWE under the allele contrast genetic model.](oncotarget-09-4200-g002){#F2}

In premenopausal individuals, thirteen included researches with 2, 029 breast cancer case groups and 2, 920 control groups were eventually included. There is no statistical correlation of rs743572 with breast cancer susceptibility in T/C model, the TT/CC, the TC/CC, the TT+TC/CC, and the TT/TC+CC (OR = 1.02 with 95% CI 0.93--1.10, OR = 1.01 with 95% CI 0.85--1.20, OR = 0.97 with 95% CI 0.83--1.14, OR = 0.95 with 95% CI 0.81--1.10, and OR = 1.04 with 95% CI 0.92--1.18, respectively). In postmenopausal women, significant correlation was found in T/C model (OR = 1.10, 95% CI = 1.03--1.17, *P* = 0.003) (Table [5](#T5){ref-type="table"}) (Figure [3](#F3){ref-type="fig"}). However, there were no significant associations between the rs743572 polymorphism and breast cancer risk in other genotype distributions: TT/CC (OR = 0.96, 95% CI =0.84--1.10, *P* = 0.539), TC/CC (OR = 0.96, 95% CI =0.85--1.08, *P* = 0.478), TT+TC/CC (OR = 0.96, 95% CI =0.85--1.08, *P* = 0.930) and TT/TC+CC (OR = 0.99, 95% CI =0.90--1.08, *P* = 0.357) (Table [5](#T5){ref-type="table"}).

![Forest plots of associations between rs743572 and breast cancer risk among postmenopausal women in the allele contrast genetic model](oncotarget-09-4200-g003){#F3}

Sensitivity analysis {#s2_3}
--------------------

Even though four researches included in our studies were not conformed to the HWE balance (*P* \< 0.05), final consequences were not changed when we excluded the abovementioned four studies. Besides, after performing the sensitivity analysis, the pooled OR values were not statistically significant changed when we delete each of the researches, indicating that this study has good stability and reliability.

Heterogeneity analysis {#s2_4}
----------------------

Heterogeneity was obtained by Q statistic. When the *P* value more than 0.1 in the *Q* test, then the fixed-effect models were selected to conduct relevant statistical analysis; otherwise, random-effect models were selected.

Publication bias {#s2_5}
----------------

No statistical evidence of publication bias was found in the Begg's test and Egger's test. What's more, funnel plot also did not show any evidence of obvious asymmetry (Table [4](#T4){ref-type="table"}) (Figure [4](#F4){ref-type="fig"}).

![Funnel plots of rs743572 and breast cancer risk in the heterozygote genetic model](oncotarget-09-4200-g004){#F4}

DISCUSSION {#s3}
==========

With the popularization and the rapid development of technology in the field of medicine, people have a deeper recognition of breast cancer. However, the specific mechanisms of the occurrence and the development of this cancer remain unclear. It is well established that estrogen involves in the development of mammary gland and plays crucial role in initiating of BC \[[@R2]\]. Extensive evidences have also been demonstrated that lifetime exposure to endogenous and/or exogenous estrogen, increased the risk of the morbidity of breast cancer \[[@R11]\]. Besides, estrogen plays a positive role of cell surface receptors of in tumorigenesis \[[@R2], [@R3]\]. Significance of genes functioning in steroid hormone synthesis is well established in breast cancer susceptibility. CYP17, a commonly known gene could code for the cytochrome P450c17α enzyme that is one of the key enzymes participated in estrogen biosynthesis \[[@R4]\]. CYP17 T-34C polymorphism, in the region (5′-UTR) of CYP17, has been reported up-regulate CYP17 transcription in some studies but not in others \[[@R7]\]. The functional impact of the T/C change is still an unresolved mystery. Moreover several studies have reported conflicting results with respect to menopausal status and CYP17 polymorphism. Hence, for the purpose of acquire a more accurate assessment of the association between rs743572 and BC risk we performed this meta-analysis whose included research studies identified in the PubMed, EMBASE and the Cochrane.

In overall populations, our results indicate no significant correlation between rs743572 and the risk of BC. Similar results could be obtained when stratified by ethnicity in all ethnic groups. In addition, confining the analysis to the researches with control groups in consistent with HWE, we also observed no correlation between rs743572 and risk of BC. Nevertheless, meaningful correlation was showed between rs743572 and breast neoplasm risk in Russian individuals \[[@R10]\]. There were three meta-analyses, all published in 2010, including 24--43 papers from different populations and demonstrated no association between the rs743572 and BC, which further demonstrate that our results are credible \[[@R12], [@R13], [@R14]\].

Estrogen is mainly produced in the ovaries and mammary glands among premenopausal women. However, in postmenopausal individuals, adipose tissue mainly acts as an important part in estrogen biosynthesis \[[@R15], [@R16]\]. Several studies have reported conflicting results of menopausal and CYP17 polymorphism: the study by Dunning *et al.* \[[@R17]\] showed the association between increased A2 genotype and premenopausal breast cancer; while Feigelson *et al.* \[[@R18]\] reported increasing frequency of A2 genotype associated with postmenopausal BC patients. We observed that rs743572 was correlated with an increasing BC risk among postmenopausal women under the allele contrast genetic model, but not in other models; however, no association was found in premenopausal women. Previous published meta- analysis reported that no association existed both in postmenopausal women and among premenopausal women \[[@R12], [@R13], [@R14]\]. Compared with them, our study used five genetic models to reduce the probability of class I errors, so our result was more reliable.

Unavoidable, there are some limitations in meta-analysis. First, breast cancer is a multifactorial disease involving genetic and environmental interactions; however, it was still not addressed the impact of gene--environmental interactions in this meta-analysis \[[@R19]\]. Second, the detailed individual information in some studies was unknown; thus, we could not assess the susceptibility of breast cancer according to other risk factors including obesity, family history, radiation therapy in young age, history of pregnancy, breast-feeding, hormone therapy and so on \[[@R20]\]. Last, there are only two studies about Africans, more well designed studies with different population should be performed to make more persuasive conclusions. In summary, our results indicate that rs743572 could increase risk of BC in postmenopausal individuals, but not in premenopausal women and the general population. Further multicenter research with complete risk factors are required to validate the potential role of rs743572 polymorphism in BC. More multicenter studies and complete risk factors are needed to further confirm the possible role of rs743572 polymorphism in the occurrence and development of breast cancer.

MATERIALS AND METHODS {#s4}
=====================

Literature and search strategy {#s4_1}
------------------------------

We searched the PubMed, EMBASE and Cochrane databases for studies performed prior to March 7, 2017 that reported an association between rs743572 SNP and breast cancer risk. There were no language restrictions in our searching process. The searching strategy was as follow: (breast cancer OR breast carcinoma) AND (polymorphism OR variant OR genotype OR SNP) AND (CYP17 OR CYP17A1 OR P450c17). Besides, the references of the retrieved studies were also reviewed to identify additional eligible studies.

Inclusion criteria {#s4_2}
------------------

The included studies must meet the following criteria: (1) case-control design; (2) investigating the association between CYP17 T-34C polymorphism and breast cancer risk; (3) sufficient genotyping data that could be used to calculate odds ratios (ORs) and 95% confidence intervals (CIs); (4) all the breast cancer subjects in case groups must be pathologically confirmed. The exclusion criteria were: (1) not case-control studies; (2) review article or commentary; (3) duplicate studies; (4) studies lacking relevant data.

Data extraction {#s4_3}
---------------

Two reviewers independently extracted the relevant data from the included studies, and discrepancies were resolved during a discussion with a third author. The following information was extracted: the first author, year of publication, country, ethnicity, source of controls, number of cases and controls, and *P* value for Hardy-Weinberg equilibrium (HWE). In addition, we also evaluated the methodological quality of included studies based on Newcastle-Ottawa Scale (NOS), which scored studies according to three aspects: selection, comparability, and exposure. Therefore, all studies could be divided into three categories: "low quality" studies (score 0--3); "moderate quality" studies (score 4--6); "high quality" studies (score 7--9).

Statistical analysis {#s4_4}
--------------------

The association between CYP17 T-34C polymorphism and BC susceptibility was measured by pooled odds ratios (ORs) and 95% confidence intervals (CIs) in five genetic models, including an allele contrast genetic model, a homozygote genetic model, a heterozygote genetic model, a dominant genetic model, and a recessive genetic model. Pooled ORs were performed for homozygote comparison (TT vs. CC for rs743572), heterozygote comparison (TC vs. CC for rs743572), dominant model (TT/TC vs. CC for rs743572), recessive model (TT vs. TC/CC for rs743572) and allelic model (T vs. C for rs743572) respectively. Statistical heterogeneity was evaluated by *I*^2^ test and *Q* test, *P* \< 0.05 was considered statistically significant. For *I*^2^ test, the criteria for heterogeneity were as follows: *I*^2^ \< 25%, no heterogeneity; 25%--75%, moderate heterogeneity; *I*^2^ \> 75%, high heterogeneity. If the *P* value of *Q* test was \< 0.1, the random-effects model was used; otherwise, the fixed-effects model was applied. Sensitivity analysis was performed by excluding one study at a time to assess the influence of each study on the pooled ORs. Begg's funnel plot and Egger's tests were used to examine publication bias and to evaluate the stability of the results by sensitivity analysis. The *P* value for Hardy-Weinberg equilibrium (HWE) in controls of every included study was calculated by Chi-square test. Subgroup analysis was performed according to ethnicity. All statistical analyses were performed using STATA version 10.0 software (StataCorp LP, College Station, TX, USA). All *P* values were two sided, and *P* \< 0.05 was considered statistically significant.

**CONFLICTS OF INTEREST**

The authors declare that no conflicts of interest exist.

[^1]: These authors contributed equally to this work
